Prognostic importance of 18F-fiuorodeoxyglucose uptake by positron emission tomography for stage III non-small cell lung cancer treated with definitive chemoradiotherapy
Küçük Resim Yok
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier Espana Slu
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Objectives: Survival heterogeneity exists among patients with non-small cell lung cancer (NSCLC), even within the same stage. We aimed to evaluate the prognostic role of pre-treatment maximum standardized uptake value (SUVmax) in patients treated with definitive concurrent chemoradiotherapy for stage III NSCLC. Materials and methods: Between 2010 and 2017, 103 patients with stage III NSCLC who underwent F-18-FDG PET/CT at the time of diagnosis were included in the study. Results: Higher tumor stages were correlated with higher pre-treatment SUVmax of lymph nodes (LNs) (p = 0.005) but were not correlated with higher SUVmax of primary tumor (p = 0.2). The median SUV max of LNs was 2.84, 8.06, and 11.11 in stage IIIa, IIIb and IIIc, respectively. Higher nodal stage was also correlated with higher SUVmax of LNs (p - 0.01). According to ROC analysis, there was no significant cut-off value of SUVmax observed for primary tumor, therefore continuous variables were used for survival analyses. The best SUVmax cut-off was 3.5 for the LNs, therefore the SUVmax of LNs was evaluated as both a dichotomous and a continuous variable. Pre-treatment SUVmax of primary tumor did not predict survival outcomes but both the continuous and dichotomous variables of SUV(max )of LNs predicted recurrence free survival and overall survival. Nodal stage (N0-2 vs. N3) and AJCC stage (IIIa vs IIIb vs. IIIc) were the other prognostic factors. Conclusions: Pre-treatment SUVmax of LNs had prognostic value in patients treated with definitive concurrent chemoradiotherapy for stage III NSCLC. In future trials, pre-treatment SUVmax of the LNs would serve as a guide for patients who might benefit from more aggressive treatments. (C) 2019 Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Medicina Nuclear e lmagen Molecular.
Açıklama
Anahtar Kelimeler
Non-Small Cell Lung Cancer, Pet/Ct, Chemoradiotherapy, Prognosis
Kaynak
Revista Espanola De Medicina Nuclear E Imagen Molecular
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
39
Sayı
1
